Table 3

Antibodies to GM-CSF and PAP in sera of patients treated with APC8015 and PA2024

Patient^a	Maximum antibody titer to GM-CSF (time to maximum response, weeks)^b	Maximum antibody titer to PAP (time to maximum response, weeks)^b
1	10,000^c (16)	0
2	20,000^c (16)	320 (8)
3	40,000 (16)	0
4	20,000 (20)	0
5	320 (8)	0
6	640 (20)	10 (4)
9	80^c,d	10 (16)
10	640 (16)	0
11	1280 (16)	160 (20)
12	80 (16)	20 (12)
13	1280 (16)	0

^a Patients 7 and 8 suffered from rapidly progressive disease, and serum was not available for testing.
^b Time to development of titer ≥10; for patients with preexisting antibodies, time to a 2-fold or larger increase in titer.
^c Patient with preexisting antibodies to GM-CSF at titers >20.
^d Preexisting titer was unaffected by treatment.